Prostate Cancer Screening

Ragsdale, John W.; Halstater, Brian; Martínez-Bianchi, Viviana

doi:10.1016/j.pop.2014.02.009

Cited by 8 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is a heterogeneous-multifocal disease with prognosis difficult to predict [27,28]. It is of great important to identify novel prognostic and predictive markers to understand this multifaceted disease process and to identify which patients need more aggressive treatment after initial curative surgery [6,7,14–16]. DNA methylation of CpG islands within the promoter region of genes is an alternative mechanism of gene silence to genetic changes and is frequently involved in the development and progression of many types of human cancers, including prostate cancer [3,4].…”

Section: Discussionmentioning

confidence: 99%

“…In recent years, with the widely adopted prostate-specific antigen (PSA)-based screening and biopsy program, the majority of prostate cancer can be detected in the early stage and can be treated by radical prostatectomy [3]. However, approximately 30% of prostate cancer patients will experience recurrence after the initial surgery and many of them will develop metastatic disease [4–7]. Prostate cancer is a heterogeneous disease in the clinical course.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Promoter Methylation of Protocadherin8 is an Independent Prognostic Factor for Biochemical Recurrence of Early-Stage Prostate Cancer

et al. 2014

View full text Add to dashboard Cite

BackgroundProtocadherin8 has been demonstrated to play critical roles in initiation and progression of several human cancers. It is frequently inactivated by promoter methylation in cancers and may be used as a potential biomarker. However, the methylation status of protocadherin8 and its clinical significance in prostate cancer remains largely unknown. The purpose of this study was to evaluate the clinical significance of protocadherin8 methylation in early-stage prostate cancer.Material/MethodsThe promoter methylation status of protocadherin8 in 162 prostate cancer tissues and 47 normal prostate tissues was examined using methylation-specific PCR (MSP). Subsequently, the relationships between protocadherin8 methylation and clinicopathological features of prostate cancer patients and biochemical recurrence-free survival of patients were analyzed.ResultsWe found that protocadherin8 methylation occurred frequently in prostate cancer tissues but not in normal prostate tissues. Moreover, protocadherin8 methylation was significantly associated with advanced pathologic stage, higher level of preoperative prostate specific antigen (PSA), higher Gleason score, positive lymph node metastasis, and biochemical recurrence. In addition, patients with protocadherin8 methylated have shorter biochemical recurrence-free survival time than patients without. Multivariate Cox regression analysis revealed that protocadherin8 methylation was an independent predictor of biochemical recurrence-free survival in prostate cancer patients.ConclusionsPromoter methylation of protocadherin8 is a frequent event in prostate cancer, and might be used as an independent prognostic factor for biochemical recurrence-free survival in patients with prostate cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Promoter Methylation of Protocadherin8 is an Independent Prognostic Factor for Biochemical Recurrence of Early-Stage Prostate Cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The varying guidelines/recommendations and lack thereof for prostate cancer screening further compound the health disparity of prostate cancer among Black men compared to White men. To address the prostate cancerscreening dilemma, shared decision-making is endorsed by leading health organizations such as the American Cancer Society and United States Preventive Task Force (Blackwelder & Chessman 2019;Ragsdale et al, 2014). The issue with using shared decision-making to receive a prostate cancer screening is that it requires men to be educated and willing to communicate about prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

An Exploration of Precancer and Post-Cancer Diagnosis and Health Communication Among African American Prostate Cancer Survivors and Their Families

2020

View full text Add to dashboard Cite

Prostate cancer is the second most common cancer among American men, with Black men at the highest risk for the disease. Few studies have been published on how communication between Black prostate cancer survivors and their family members affect health outcomes and subsequent health communication. The purpose of this study was to understand cancer and health communication among Black prostate cancer survivors and their families before and after disclosing their diagnosis. Through a mixed method design, 11 Black prostate cancer survivors participated from the Southeastern region of the United States, completed questionnaires, and took part in a focus group. The study utilized 4 focus groups of Black prostate cancer survivors ranging in age from 51 to 76 years. Descriptive statistics revealed 91% ( n = 10) of participants indicated they could openly discuss health issues in their family and 82% ( n = 9) indicated a female relative as the person responsible for teaching about health. An analysis of the transcripts revealed four themes utilizing thematic network: (a) communication over the life course of the prostate cancer survivor, (b) parents’ communication with family, (c) disclosing prostate cancer diagnosis, and (d) treatment options for prostate cancer. Results suggested the participants recognized the importance of discussing prostate cancer with their families to reduce fears and misconceptions about the disease. Through the exploration of cancer and health communication within Black families, solutions can be derived for increasing health behaviors and health knowledge among men.

show abstract

“…For patients with localized disease, radical prostatectomy is a potentially curable treatment. Unfortunately, approximately 30% of patients will experience recurrence after the initial therapy and then subsequently developing metastatic disease [5–8]. Currently, the conventional clinicopathological parameters, such as serum prostate-specific antigen (PSA), pathological Gleason score, and tumor stage, are commonly used to predict patient outcome after initial management, but the accuracy of this prediction remains unsatisfactory for many patients [9–11].…”

Section: Introductionmentioning

confidence: 99%

Aberrant Methylation of Protocadherin 17 and its Clinical Significance in Patients with Prostate Cancer after Radical Prostatectomy

et al. 2014

View full text Add to dashboard Cite

BackgroundAberrant methylation of protocadherin 17 (PCDH17) has been reported in several human cancers. However, the methylation status of PCDH17 in prostate cancer and its clinical significance remains unclear. The aim of this study was to investigate the methylation status of PCDH17 and its clinical significance in patients with prostate cancer after radical prostatectomy.Material/MethodsThe methylation status of PCDH17 in 152 prostate cancer tissues and 51 non-tumoral prostate tissues was examined by methylation-specific PCR (MSP). Then the association between PCDH17 methylation and clinicopathologic parameters was analyzed. Kaplan-Meier survival analysis, log-rank test and multivariate Cox proportional hazard model analysis were used to analyze the correlation between PCDH17 methylation and prognosis of patients with prostate cancer.ResultsOur data demonstrated that PCDH17 methylation occurred frequently in prostate cancer. PCDH17 methylation was significantly associated with higher pathological Gleason score (P=0.0315), advanced pathological stage (P=0.0260), higher level of preoperative PSA (P=0.0354), positive angiolymphatic invasion (P=0.0461), positive lymph node metastasis (P=0.0362), and biochemical recurrence (BCR) (P=0.0018). In addition, PCDH17 methylation was an independent predictor of poor biochemical recurrence-free (BCR-free) survival and overall survival for patients with prostate cancer.ConclusionsPCDH17 methylation is a frequent tumor-specific event in prostate cancer, and is significantly correlated with shorter BCR-free survival and overall survival of patients with prostate cancer after radical prostatectomy. PCDH17 methylation in tumor samples after radical prostatectomy may be used as an independent prognostic biomarker.

show abstract

Prostate Cancer Screening

Cited by 8 publications

References 34 publications

Promoter Methylation of Protocadherin8 is an Independent Prognostic Factor for Biochemical Recurrence of Early-Stage Prostate Cancer

Promoter Methylation of Protocadherin8 is an Independent Prognostic Factor for Biochemical Recurrence of Early-Stage Prostate Cancer

An Exploration of Precancer and Post-Cancer Diagnosis and Health Communication Among African American Prostate Cancer Survivors and Their Families

Aberrant Methylation of Protocadherin 17 and its Clinical Significance in Patients with Prostate Cancer after Radical Prostatectomy

Contact Info

Product

Resources

About